We are experts in the development of robust drug products
United by passion and expertise in solid dosage form development, we bring a century of combined R&D experience, leading to the successful development of over 70 products.
We tackle development hurdles in a hands-on and practical way, always aiming for sturdy formulations and processes. Whether we are working on tablets or soft capsules, be it immediate or modified release, our focus is on robust formulations and processes.
Our team brings expertise across the spectrum of solid oral dosage forms, covering formulation development, analysis, manufacturing, as well as biopharmaceutical and regulatory aspects.
Leveraging a robust CDMO background, we enhance our technological expertise with valuable insights into commercial, contractual, and intellectual property matters.
-
Dr. Armin Prasch, Partner and CEO
Armin’s core competencies lie in R&D strategy, intellectual property, sourcing, and equipment aspects. Over the past few years, he developed a profound expertise in medicinal cannabis. A board member of the German Association of the Cannabis Industry (BvCW e.v.), he leads the working group for medicinal cannabis and is a member of the expert group on medicinal cannabis of the German Pharmaceutical Association DPhG.
Armin is widely acknowledged for his expertise in medicinal cannabis and is frequently invited as a speaker at conferences in the German medicinal cannabis sector. During his career Armin held senior leadership roles at Glatt, ADD Technologies, and as SVP R&D at the CDMO Aenova. Armin is the inventor of various patents relating to solid oral dosage forms. He holds a PhD in Chemical Engineering from the University of Munich.
-
Dr. Burkhard Schlütermann, Partner and CSO
Pharmacist with a PhD in pharmaceutical technology and 30+ years of experience in the pharmaceutical industry, Burkhard has led technical R&D operations at Aenova, ADD Technologies, Novartis, and Ciba-Geigy. With profound expertise in pharmaceutical and analytical development, biopharmaceutical, and regulatory aspects, he has been very successful in obtaining marketing approval for NDAs and generic applications, both in the US and EU with immediate- and modified-release drug products. His experience includes the creation of a network of CROs, as well as organizing and taking over sponsor responsibility for various pharmacokinetic studies. He is the inventor of various patents relating to solid oral dosage forms
-
Yanitsa Miteva, Partner and COO
A pharmacist with 15 years of experience in pharmaceutical R&D, Yanitsa is an expert in the development of soft capsules and covers a range of competencies in the technical and business aspects of projects, such as sales, business development, and technical operations. At Trias Pharma and in her previous role as responsible for customer development projects and R&D Sales at Aenova, she oversaw a wide portfolio of development, transfer, and troubleshooting projects and successfully managed various contract generic and line-extension development soft gel projects for EU and US markets.
She is a recognized speaker at technical conferences on soft gelatin capsules.
-
Michel Pommerette, Senior Consultant
Michel is a pharmaceutical engineer with 25+ years of experience in the development of specialty solid dosage forms and drug powder inhalers. An expert in formulation development of complex dosage forms and combination products, he has managed the CMC aspects and brought a variety of specialty solid dosage forms to registration. Michel´s area of expertise covers the transfer and scale-up of drug products, manufacturing process validation, quality engineering, and GMP aspects including manufacture of clinical supplies and CMC coordination.
His previous roles include scientific and project management positions at Jago Pharma, Skyepharma, Aenova, Novartis, and Consultys.